Exo Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
480 Arsenal Way, Watertown, Massachusett...Website
www.exo-therapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Exo Therapeutics
Based out of Boston, MA, Exo Therapeutics is a biopharmaceutical company with a focus on small molecule drug discovery and development.Explore more
Exo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Exo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Exo Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Exo Therapeutics launches new products
Click to see if Exo Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Exo Therapeutics is spiking on competitors!
Earning: See what the market has to say on Exo Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Exo Therapeutics has new funding data
Check if Exo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Exo Therapeutics
Find more new buyers
Compare Similar Companies to Exo Therapeutics
Compare insights from companies similar to Exo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Exo Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Exo Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Exo Therapeutics.
Exo Therapeutics financials insights
Gather financial insights about Exo Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$25M
2021
Series B
$78M
Exo Therapeutics Tech Stack
A closer look at the technologies used by Exo Therapeutics
Most Recent Scoops
Executive Move
Nagesh Mahanthappa has assumed the role of Executive Chair on the organization's Board of Directors.
Board of Directors
Left Company
Executive Move
Shilpi Arora, Vice President, Discovery and Translational Biology, has left the organization and now serves as Senior VP, Discovery Research at Transition Bio, Inc..
Left Company
Executive Move
New Hire
Executive Move
Exo Therapeutics News & Media
Exo Therapeutics Announces Late Breaking Poster at American College of Rheumatology’s Convergence (ACR)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics, Inc., a pre-clinical company developing a pipeline of drug candidates that target exosites, unique small-molecule binding pockets that are distal to traditional active and allosteric sites, thereby reprogramming enzyme activity for precise and robust therapeutic effect, announced a late breaking poster presentation at American College of Rheumatology’s Convergence (ACR) taking place November 14-19, 2024 in Washington, D.C. Details of the postExo Therapeutics Presents Key Data at FOCIS 2024 Demonstrating the Efficacy of Potent and Selective Exosite-targeted TBK1/STING Inhibitor in Multiple Preclinical Models
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics presents on its preclinical program targeting TBK1/STING interaction of the cGAS-STING pathway at FOCIS 2024.Exo Announces Lead Program, Targeting TANK Binding Kinase 1 (TBK1), for the Treatment of Autoimmune Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exo Therapeutics announces its lead program directed against TBK1, and the appointment of Alexandra Joseph, PhD, as Executive Vice President, Biology.Exo Therapeutics Appoints Nagesh Mahanthappa as Executive Chair
WATERTOWN, Mass.--(BUSINESS WIRE)--Dr. Mahanthappa joins Exo as Executive Chair after serving on the Board of Directors since March 2021.
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Exo Therapeutics
Sign Up For FreeTo access detailed company insights
Based out of Boston, MA, Exo Therapeutics is a biopharmaceutical company with a focus on small molecule drug discovery and development.... Read More
